Navigation Links
ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
Date:2/23/2009

escalating doses of TB-402. It is anticipated that the study will conclude by the end of 2010.

Patrik De Haes, CEO of ThromboGenics, commented on today's news "We are very excited about the start of the Phase II trial for TB-402. Our work to date suggests that this novel agent could represent a major advance in anti-coagulant therapy, given our expectation that it will cause fewer unwanted bleeding events and will require no monitoring of patients. This combined with its ability to be used as a "one-off" treatment could make TB-402 the anti-coagulant of choice to prevent DVT in patients undergoing surgery. Given the size of the market opportunity for TB-402 and the sales reach that will be needed to engage with the potential prescribers of TB-402, it is our intention to seek a partner to undertake the later stage development and commercialisation of this exciting new agent."

Svein Mathisen, CEO of BioInvent, also commented, "The initiation of this Phase II trial is another successful step forward in the clinical development of our antibody product development portfolio. TB-402 addresses a broad market and has potentially significant advantages over existing anti-coagulants. We are hopeful it will have application in a number of clinical settings."

About Deep Vein Thrombosis (DVT)

DVT is caused when a blood clot forms in a deep vein, most commonly in the deep veins of the lower leg. DVT is a major public health issue and it is estimated that in the U.S. alone, more than 350,000 individuals are affected by DVT or pulmonary embolism (PE) each year. Moreover, DVT and PE together may be responsible for more than 100,000 deaths in the U.S. each year.(1)

It is estimated that by 2015, 1.4 million patients will undergo knee replacement and 600,000 patients will undergo hip replacement in the U.S. if current trends persist.(2) Patients undergoing hip replacement or knee surgery are p
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ThromboGenics N.V.: Business Update
2. ThromboGenics Announces Half Year Results 2008
3. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
4. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
5. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
6. ThromboGenics N.V. - Business Update
7. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
10. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
11. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... METTLER TOLEDO's web-based ... the product choices to a manageable shortlist of bench and floor scales and ... that fit best with the customer’s industry and application. , Side-by-side product ...
(Date:8/26/2015)... ... August 26, 2015 , ... MediVet Biologics, a leader ... laboratory is to open in Manhattan, Kansas in early October, 2015. The location ... of research and development through collaboration with researchers from Kansas State University’s College ...
(Date:8/26/2015)... ... August 26, 2015 , ... Lee Biosolutions, ... the development and manufacture of highly valued cardiac markers used in early detection ... expertise with protein chemistry has led to the development and commercialization of important ...
(Date:8/26/2015)... , Aug. 26, 2015 Intrexon Corporation (NYSE: ... today the closing of its previously announced public offering ... the underwriters of their option to purchase an additional ... price of $41.00 per share.  The exercise of the ... common stock sold by Intrexon to 5,609,756 shares and ...
Breaking Biology Technology:METTLER TOLEDO Updates Online Scale Selection Tool 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4
... CLEVELAND, Ohio, June 2 Simbionix has announced ... its LAP Mentor simulator that,gives trainees hands-on experience ... of ectopic pregnancy, tubal,sterilization and oophorectomy., The ... suite of laparoscopic,procedures developed for the LAP Mentor, ...
... Clinical Oncology Proves Accurate, Measurement of ER and PR ... ... June 2 Genomic Health,Inc. (Nasdaq: GHDX ) today ... a study confirming RT-PCR by Oncotype DX can,deliver quantitative gene ...
... June 2 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V:,QPT), ... 12-patient,Phase I clinical study entitled "ACP-SL017 Topical Gel: ... Actinic Keratosis" has met both its primary and,exploratory ... for the first time, clinical,validation for our SonoLight ...
Cached Biology Technology:Simbionix Takes Non-Invasive GYN Surgical Training to the Next Level 2Genomic Health Announces Expansion of Oncotype DX(R) Breast Cancer Test to Include Quantitative Estrogen Receptor (ER) and Progesterone Receptor (PR) Scores 2Genomic Health Announces Expansion of Oncotype DX(R) Breast Cancer Test to Include Quantitative Estrogen Receptor (ER) and Progesterone Receptor (PR) Scores 3Genomic Health Announces Expansion of Oncotype DX(R) Breast Cancer Test to Include Quantitative Estrogen Receptor (ER) and Progesterone Receptor (PR) Scores 4Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis 2Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis 3
(Date:8/6/2015)... , Aug. 6, 2015  Today, U.S. ... visit Crossmatch ™ to learn firsthand how ... protect data. Crossmatch is a world leader in ... and expertise are helping federal agencies and commercial ... security.   "The vast majority of ...
(Date:8/5/2015)... CHICAGO , August 5, 2015 ... Identity & Access Management Market by Software, Services, Vertical (BFSI, ... Chemical/Pharma), & Geography - Global Forecast to 2020", published ... Access Management Market globally into various segments. The global ... in 2014 to $546.2 Million by 2019, at a ...
(Date:8/4/2015)... , Aug. 04, 2015 ... ) has announced the addition of the ... Software, and Service), Sub-Segment (Computer Forensics, Network ... Tool Types, Service, Vertical and Region - ... their offering. By Component (Hardware, ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... One of the smallest parts of the brain is getting ... crucial role in decision making. A University of British ... the lateral habenula, a region of the brain linked to ... be integral in cost-benefit decisions. "These findings clarify the ...
... -- Many owl species have developed specialized plumage to effectively ... to hunt and capture their prey in silence. ... how owls achieve this acoustic stealth will present their findings ... meeting, held Nov. 24 26, in Pittsburgh, Pa. -- ...
... Greenland,s ice sheet is small today? It was smaller ... from 3-5,000 years ago, according to scientists who studied the ice ... Arctic fossil record. "What,s really interesting about this is that ... ago, maybe as late as 4,000 years ago. The oceans, on ...
Cached Biology News:Scientists find brain region that helps you make up your mind 2The secrets of owls' near noiseless wings 2Greenland's shrunken ice sheet: We've been here before 2Greenland's shrunken ice sheet: We've been here before 3
... mini, SSM3 & SSM4, Small space saving design ... , Choice of two models: , - 3D ... , Digital speed control and built-in timer ... ,These compact rockers are ideal where gentle mixing is ...
...
... a partial recombinant MAK. Immunogen: ... partial recombinant protein with GST tag. ... Accession: BC039825 Protein Accession ... 154235, GeneID: 4117 ...
Mouse monoclonal antibody raised against a full length recombinant PPIL2. NCBI Entrez Gene ID = PPIL2...
Biology Products: